Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil. (linkinghub.elsevier.com)

Authors: Buerger V … Jaramillo JC Journal: Lancet Infectious Diseases Published: 2026-04-01 DOI: https://doi.org/10.1016/S1473-3099(25)00631-0